Hepatitis C therapy-the future looks bright

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 28, Issue 12, 2009, Pages 1409-1413

  Qureshi, Sohail A ^a   Qureshi, Humaira ^a   Hameed, Anam ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ANTIVIRUS AGENT; BOCEPREVIR; ITMN-191; MK0608; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PF868544; R 7128; RIBAVIRIN; SCH900518; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG;

HEPATITIS C; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HEPATITIS C; HUMANS;

EID: 71349084633     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0798-1     Document Type: Review

References (16)

1. MJ Evans T von Hahn DM Tscherne AJ Syder M Panis B Wölk T Hatziioannou JA McKeating PD Bieniasz CM Rice 2007 Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 7137 801 805 10.1038/nature05654 1:CAS:528:DC%2BD2sXktVeqtrs%3D 17325668 (Pubitemid 46582027)
2. SA Qureshi 2007 Hepatitis C virus-biology, host evasion strategies, and promising new therapies on the horizon Med Res Rev 27 3 353 373 10.1002/med.20063 1:CAS:528:DC%2BD2sXmtVGrt7Y%3D 16958135 (Pubitemid 46668938)
3. M Silva J Poo F Wagner M Jackson D Cutler M Grace R Bordens C Cullen J Harvey M Laughlin 2006 A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE) J Hepatol 45 2 204 213 10.1016/j.jhep.2006.03.008 1:CAS:528:DC%2BD28Xmslylur0%3D 16780997
4. S Le Pogam A Seshaadri A Kosaka S Chiu H Kang S Hu S Rajyaguru J Symons N Cammack I Nájera 2008 Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 6 1205 1216 10.1093/jac/dkn085 18343801 (Pubitemid 351753583)
5. PJ Pockros D Nelson E Godofsky M Rodriguez-Torres GT Everson MW Fried R Ghalib S Harrison L Nyberg ML Shiffman I Nájera A Chan G Hill 2008 R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin Hepatology 48 2 385 397 10.1002/hep.22357 1:CAS:528:DC%2BD1cXhtVCqt73I 18570306
6. Pharmasset Inc. (2009) R7128, a prodrug of PSI-6130. Home page at: http://www.pharmasset.com/pipeline/R7128.asp
7. SS Carroll S Ludmerer L HAndt K Koeplinger NR Zhang D Graham ME Davies M Maccoss D Hazuda DB Olsen 2009 Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees Antimicrob Agents Chemother 53 3 926 934 10.1128/AAC.01032-08 1:CAS:528:DC%2BD1MXivF2ltbg%3D 19075052
8. Troke P, Lewis M, Simpson P, van der Ryst E, Hammond J, Craig C, Perros M, Westby M (2009) Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. In: Poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL), Copenhagen, Denmark, April 2009
9. Vertex Phamaceuticals (2008) Telaprevir presentations at the 59th AASLD meeting to feature SVR data in treatment-naïve and treatment-failure genotype 1 HCV patients, and clinical data exploring twice-daily dosing regimens. Available online at: http://investors.vrtx.com/releasedetail.cfm? ReleaseID=336431
10. RB Perni SJ Almquist RA Byrn G Chandorkar PR Chaturvedi LF Courtney CJ Decker K Dinehart CA Gates SL Harbeson A Heiser G Kalkeri E Kolaczkowski K Lin YP Luong BG Rao WP Taylor JA Thomson RD Tung Y Wei AD Kwong C Lin 2006 Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 3 899 909 10.1128/AAC.50.3.899-909.2006 1:CAS:528: DC%2BD28XisFamt70%3D 16495249 (Pubitemid 43327793)
11. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, Davis M, Galati J, Gordon S, Ravendhran N, Rossaro L, Anderson F, Jacobson I, Rubin R, Koury K, Chaudhri E, Albrecht J (2008) Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients: interim results from the HCV SPRINT-1 study. In: Proceedings of the 59th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, California, October/November 2008
12. Schering-Plough (2009) Final results of boceprevir phase II HCV SPRINT-1 study showed significantly higher SVR rates compared to standard of care in treatment-naive genotype 1 hepatitis C patients. Available online at: http://www.schering-plough.com/news/news-article.aspx?reqid=1279938
13. Medivir (2008) Focus on hepatitis C. Home page at: http://www.medivir.se/ v3/en/
14. NATAP (2008) Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6. Available online at: http://www.natap.org/2008/AASLD/ AASLD-23.htm
15. InterMune (2009) InterMune reports results from triple combination study of ITMN-191. Available online at: http://phx.corporate-ir.net/phoenix.zhtml?c= 100067&p=irol-newsArticle&ID=1243000&highlight=
16. NATAP (2008) Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Available online at: http://www.natap.org/2008/AASLD/AASLD-26.htm